Fulcrum Therapeutics cuts workforce, retaining only nine employees as layoffs hit 48 staff

Fulcrum Therapeutics announced a dramatic reduction in its staff, letting go of 48 of its 57 full‑time employees. The move leaves the company with just nine remaining workers, effectively turning it into a shell organization.

The layoffs were disclosed in a recent SEC filing, which confirmed the scale of the workforce cut. No specific reasons were provided in the filing beyond the reduction itself.

In the same briefing, Seres Therapeutics reported that it has extended its financial runway through 2027, though details on how this was achieved were not included in the brief report.